, ,

Texas Just Made History: $50M Approved for Ibogaine Research

Texas just made history. With the passage of House Bill 3717 and Senate Bill 2308, the State of Texas has committed $50 million to fund ibogaine research — the largest publicly funded psychedelic research initiative in the world.

This is a turning point for the thousands of people, especially Veterans and first responders, who have been left with few options in the face of trauma, addiction, and chronic emotional pain.

Beond is proud to support this historic effort. As a global leader in medically supervised ibogaine treatment, we’ve conducted over 3,000 treatments with hospital-grade safety protocols, ICU-certified staff, and a clinical model built on trust, dignity, and science.

Through our nonprofit arm, Beond Service, we’ve created a dedicated pathway for Veterans, first responders, and their spouses to receive trauma-informed care, full-spectrum reintegration support, and the chance to reclaim their lives.

This is a message to those at the end of hope: you have not been forgotten.
To lawmakers across the U.S.: Texas showed what leadership looks like.
To the world: ibogaine is no longer on the fringe. It’s at the forefront.

We’re honored to be part of this movement and deeply grateful to everyone who helped push this initiative forward, from the Veterans who courageously shared their stories, to the policy makers, advocates, and behind-the-scenes organizers who made this moment possible.

Working alongside Texas Ibogaine Initiative, W. Bryan Hubbard, Rick Perry, and so many others, we’re committed to what comes next.

And we’re ready to bring this medicine home, safely, ethically, and at scale.


/0 Comments/by
,

Texas Takes a Historic Step Toward Legal Ibogaine Research

In a landmark move for the future of psychedelic-assisted therapy in the U.S., the Texas House of Representatives has given strong bipartisan support to SB2308/HB3717 — a bill that would fund ibogaine research through a newly established state grant program.

With 141 votes in favor, this is the most significant psychedelic therapy vote in Texas history.

If enacted, this legislation will allocate $50 million to fund FDA-approved clinical trials studying ibogaine’s potential to treat opioid use disorder (OUD), PTSD, traumatic brain injury (TBI), and other serious mental health conditions. The goal: accelerate FDA approval and expand safe, evidence-based access to those in need.

At Beond, we are deeply encouraged by this momentum. As Tom Feegel, CEO and Co-Founder of Beond, shared earlier this year, “This couldn’t be more historic or more important at this moment.”

The legislation reflects growing recognition that traditional treatments often fall short — and that alternative, science-backed therapies like ibogaine deserve rigorous research and public support.

“Ibogaine isn’t just another drug. It’s a whisper of redemption in a single dose… It can mend the broken pieces of a mind ravaged by trauma.”
— Rep. Cody Harris (R), bill sponsor

Texas is again leading the national conversation, building on earlier psychedelic research initiatives like HB1802 and showing what’s possible when science, safety, and service align.

We’re encouraged by this momentum and hopeful that with continued leadership, safety, science, and honoring its cultural roots, this medicine can reach more of those who truly need it.



/by
,

Fitness Guru Jillian Michaels Highlights the Benefits of Ibogaine

In a recent appearance on Fox’s The Will Cain Show, Jillian Michaels discusses a Texas bill that would fund research into the powerful plant medicine ibogaine.

What to Know About Ibogaine

Ibogaine is a powerful, non-addictive plant medicine helping people heal from trauma, PTSD, and opioid dependency — often in just one treatment.

Yet in the U.S., it remains classified as a Schedule I substance, meaning it’s considered dangerous with no accepted medical use — despite mounting evidence to the contrary.

That’s why people are traveling to Mexico for legal, medically supervised treatment like we offer at Beond, where safety includes full cardiac screening, 24/7 ICU-trained nurses, and integrative support.

But more options should be available for those in the U.S. who can’t travel — or prefer not to.

The Texas Ibogaine Initiative is pushing to change this. Two new bipartisan bills (HB 3717 & SB 2308) could help bring ibogaine into FDA-approved trials and expand access to life-saving care.

Here’s How You Can Help:

– Go to rallytexas.org and take 20 seconds to contact Texas lawmakers.
– Forward this post to 10 friends — especially those in Texas.
– Share this blog post or add it to your stories on social media.

It’s about real people, real healing, and a future where access to care doesn’t depend on your passport.

/by
, ,

Reconnecting Through Ibogaine: Insights from Beond’s Founders on The New Health Club Podcast

Addiction isn’t just about substances. It’s about disconnection, from self, from others, from something greater.

In this conversation on The New Health Club podcast, Beond co-founders Tom Feegel and Talia Eisenberg share how psychedelics like ibogaine help us reconnect. To our inner truth. To each other. To the parts of us we thought were lost. They also dive into why ibogaine is gaining global attention.

They talk:

– The neuroscience of ibogaine’s reset
– PTSD, trauma, and the roots of addiction
– Why healing must include both clinical excellence and cultural reverence
– What it really means to feel safe in a treatment setting

This conversation delves into the science, cultural significance, and personal impact of Ibogaine therapy. If we rethink addiction treatment, could we finally turn the tide on the opioid crisis?

Watch here:


Key Takeaways from This Episode of The New Health Club podcast:

– Ibogaine is becoming more mainstream. Once an underground therapy, it’s now entering the public discourse.
– It offers real potential for addiction and PTSD treatment. Ibogaine works at a neurological level to reset brain chemistry and interrupt addictive patterns.
– Cultural and spiritual roots matter. Ibogaine isn’t just a treatment—it’s a profound experience with indigenous origins.
– Unlike other psychedelics, Ibogaine’s effects can last up to 48 hours. It’s intense, immersive, and deeply introspective.
– Healing is both clinical and spiritual. The best results come from clinics integrating modern medicine with ancient wisdom.
– Recovery is more than breaking addiction—it’s redefining identity. True healing requires personal growth, new perspectives, and community support.
– Addiction is often a symptom of deeper emotional pain or trauma. Addressing the root cause, not just the behavior, is essential.
– Peer-to-peer support is crucial. The recovery process is enhanced by those who have walked the same path.

Listen here:


After W. Bryan Hubbard’s powerful appearance on the Joe Rogan Experience, Beond saw a surge of interest—and it got me thinking: Could this be the moment when Ibogaine finally gets the recognition it deserves?

/by
, ,

Understanding the Differences Between Ibogaine and Ayahuasca

Ibogaine the same as Ayahuasca? Short answer? No. Both are sacred plant medicines, but their experiences and mechanisms are very different.

— Ibogaine creates a oneiric, dreamlike state, often described as a deep internal life review.
— Ayahuasca can feel more like traveling through other dimensions.

Neurologically:

— Ibogaine helps reset dopamine and serotonin systems, increases GDNF (a key neurotrophic factor), and promotes long-term neuroplasticity. It can interrupt addiction, reduce cravings, and support cognitive enhancement, PTSD recovery, and emotional clarity with lasting effects.

— Ayahuasca is more commonly associated with ego dissolution.

With ibogaine, you’re clear, grounded, and deeply introspective. Both can be powerful healing tools, but ibogaine uniquely targets the brain and nervous system to help break long-standing patterns at their root.

Watch: Beond’s Co-Founder, Talia Eisenberg Explains the Key Differences Between Ibogaine and Ayahuasca


/by
, , ,

The Future of Ibogaine in the U.S.

Beond’s co-founder, Tom Feegel, is in Austin, Texas, standing alongside Beond Service alumni and veteran advocates to support HB 3717, a groundbreaking bill introduced by Rep. Cody Harris.

This legislation seeks $50 million in state funding for FDA-approved clinical trials of ibogaine, a potential game-changer for PTSD, traumatic brain injury (TBI), opioid use disorder, and other mental health conditions.

Texas is once again at the forefront of medical innovation, building on the momentum of HB 1802 to explore psychedelic therapies.

With support from the Texas Ibogaine Initiative and the American Ibogaine Initiative, this bill could revolutionize addiction and mental health treatment, paving the way for safe, evidence-based access in the U.S.


#TexasIbogaineInitiative

Beond’s Commitment to Veterans and Ibogaine Research

“We are here in Austin to support the Texas Ibogaine Initiative with alumni from Beond Service,” says Tom Feegel. “Beond Service is our nine-week, zero-cost program dedicated to helping veterans who need treatment for PTSD and TBI receive ibogaine in the best possible way.”

@beond.us 🇺🇸 Lawmakers in Texas are pushing to fund $50M for ibogaine research.This could change everything. It’s time. #beondibogaine #texasibogaineinitiative #americanibogaineinitiative #ibogainetreatment ♬ original sound – Beond Ibogaine Treatment


The Texas Ibogaine Initiative is supported by the REID Foundation and led by W. Bryan Hubbard, the Executive Director of the American Ibogaine Initiative. Their mission is to help lawmakers allocate $50 million for research into ibogaine—a treatment that has already demonstrated transformative potential but requires formalized data to advance FDA approval for use in the United States.

“This couldn’t be more historic or more important at this moment”

The approval of HB 3717 could mark a turning point for ibogaine therapy in the U.S., providing a structured path toward integrating this powerful treatment into mainstream medical care.

With growing bipartisan support for psychedelic research, Texas continues to lead the way in rethinking mental health and addiction treatment solutions.

Related Post: Veteran’s Journey: How Ibogaine Therapy Addressed PTSD, TBI, and Opioid Dependency

/by
, ,

Ibogaine’s Potential Spotlighted on The Joe Rogan Experience

On The Joe Rogan Experience, former Texas Governor Rick Perry and Bryan Hubbard, the first Chairman of the Kentucky Opioid Commission and director of the REID Foundation’s American Ibogaine Initiative, discussed the transformative potential of ibogaine. Their conversation explored how ibogaine can address addiction, trauma, PTSD, and mental health challenges—particularly for veterans.

Yet, despite its incredible potential and lack of addictive properties, ibogaine remains a Schedule 1 substance in the U.S., severely limiting its availability and research.

During the conversation, Bryan Hubbard highlighted the critical role of safety and care in ibogaine treatment, acknowledging Beond as a trusted clinic leading the way with the highest standards of care.

At Beond, we’ve witnessed firsthand the transformative power of ibogaine—helping hundreds of guests overcome addiction, find relief from anxiety, depression, and PTSD, and even enhance their cognitive abilities. This groundbreaking conversation brings us one step closer to making these life-changing treatments more widely available.

Rick Perry was the 47th governor of Texas and the 14th secretary of Energy in the first administration of President Donald Trump.

W. Bryan Hubbard was the 1st Chairman of the Kentucky Opioid Commission and currently leads the REID Foundation’s American Ibogaine Initiative.



/by
,

Why Our New Study Shows Ibogaine Can Help Treat Alcohol Dependency

 

Beond Treatment

In 1962, Howard and Norma Lotsof stumbled on the fact that ibogaine can help with opioid addiction.

Then, for 60 years, researchers have studied ibogaine’s effects on addiction to opioids and cocaine. They’ve consistently found that ibogaine can help with the cravings, withdrawals, sadness and depression that come along with opioid and cocaine addiction.

But ibogaine researchers haven’t studied alcohol very much. That’s despite the fact that alcohol is the drug of abuse that’s most commonly used by most people. And the fact that alcohol can actually do as much damage as opioids or cocaine.

Today, Beond is helping fill the gap in scientific knowledge about ibogaine and alcohol.

We conducted our own research study. Our simple question was: can ibogaine contribute to recovery from alcoholism? Our findings are striking.

Guests with alcohol dependency who went through our treatment program said they left feeling happier, less anxious, and with fewer withdrawal symptoms.

Note: Our study shows preliminary patient outcomes, which need to be further validated through the peer-review process. But we wanted to share our initial findings with our community.

Here are the basics of our research study, in plain English.

What Alcohol Dependency Is

Alcohol Dependency occurs when people feel like they need to drink, even when they know it can harm their health, relationships, or daily responsibilities. They may ignore liver damage or lost income. They might even hide flasks from loved ones, sneak sips between business meetings, or chug liquor in the bathroom.

Seventeen percent of Americans binge drink, and seven percent drink heavily. Drinking too much kills three football stadiums worth of people each year.

For many, stopping drinking can feel as difficult as stopping breathing, or giving up sunshine. Why? There are social, physical, and emotional challenges. First, if everyone around you is drinking, it’s hard to be the odd one out. Second, if you quit, there are withdrawal symptoms—especially if you’re a super-heavy drinker. Third, if you do quit, anxiety and depression are common, making recovery even harder.

Worse, traditional treatments, such as medication, twelve-step programs, and behavioral therapy, for alcohol dependency are often under-utilized due to stigma or a shortage of professional support. Relapse rates are around 60 percent.

All these negative effects leave room for relapse.

What Ibogaine Is

Our study explores the efficacy of ibogaine in treating alcohol dependency.

Ibogaine is a psychedelic substance from the African plant Tabernanthe iboga.

It’s traditionally used in Central Africa by the Fang, Pygmy, and Babongo tribes for spiritual ceremonies in their Bwiti religion. For them, iboga is akin to communion wine.

Ibogaine came to light in the West in the 1960s, after a couple named the Lotsofs found ibogaine eased the cravings for opioids. One dose of ibogaine, they found, and a person might no longer be dopesick.

There have been a few promising signs that ibogaine could treat alcoholism. Studies in rodents show that ibogaine can reduce self-administration of alcohol. And small case studies of humans, including veterans, suggest ibogaine can help reduce troublesome alcohol use.

Medical Care is Key

Our ibogaine treatments last about 12 hours. They can be risky, as ibogaine can cause severe side effects like an irregular heartbeat, especially in people with pre-existing heart conditions. Ibogaine can also cause nausea, vomiting, and dizziness. That’s why it’s important for a study of ibogaine to happen at a place like Beond.

Medical Care is Key

We are a well-equipped medical facility with some of the best ibogaine doctors and nurses. We carefully screen our guests to make sure they’re fit for treatment. And we monitor the whole person—especially their hearts—during and after their ibogaine sessions to make sure our guests stay safe.

Study Goals

For this study, we closely observed the impact of ibogaine treatment on patients with alcohol dependency as they stopped using the drug. We wanted to see if ibogaine could lessen their withdrawal symptoms and improve their mental health.

Who Was in Our Study

Fifty-eight guests (21 women and 37 men) who had alcohol dependency took part. The average age of patients was 39 years. Our guests had to have signs of misuse, including difficulty in cutting back or feeling the need for treatment.

To be considered as having alcohol dependency, patients needed to be drinking heavily. That means at least four drinks three times per week for the last six months. On average, patients reported they drank about 6 days a week, having 7 drinks per day. That’s 42 drinks a week. On average, they had been struggling with alcohol misuse for nearly 20 years.

Before starting treatment, guests were asked to avoid alcohol for a week. Not all managed to do so.

How We Measured Guests’ Troubles

Upon their arrival and prior to departing Beond, each guest completed the following surveys twice to assess their anxiety, depression, and withdrawal symptoms before and after ibogaine treatment.

— The Beck Anxiety Inventory: A survey with 21 questions asking questions about anxiety like: “How often do you feel heart pounding, hands trembling, or fear of dying?”

— The Beck Depression Inventory: Another 21-question survey asking about depression. People reported their depressive thoughts, such as “I am so sad and unhappy I can’t stand it,” “I feel I am a complete failure as a person,” and “I would kill myself if I had the chance.”

— Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised: People who are quitting alcohol report whether they feel nausea, itching, pins and needles, whether their arms are trembling, or whether they even know what day it is—all typical signs of alcohol withdrawal.

Treatment Process

The study participants went through the typical Beond program. Each did a 10 or 14-day inpatient program at our clinic in Cancun, Mexico, sometime between March 2022 and March 2024.

They received comprehensive medical and psychological care. Each guest had heart monitoring, blood tests, and drug screenings. Patients who could abstain from alcohol for a week before arriving had a slightly shorter treatment duration—10 days instead of 14.

On treatment days, patients received doses of ibogaine. The amount was carefully calculated based on factors like age, weight, and medical history. The average dose was 8–12 mg per kg of body weight. Patients were monitored closely for 12 hours, as ibogaine can affect the heart. After treatment, patients participated in counseling, well-being activities, and discharge planning. For some, additional smaller doses of ibogaine, called “boosters,” were administered.

Study Finds Less Anxiety, Depression and Withdrawal

After the treatments, we studied the survey responses. How did our alcohol-dependent guests feel before going through our ibogaine treatments? And how did they feel afterward? Was there a difference?

The results were promising. Across the three key areas—anxiety, depression, and withdrawal—patients experienced notable improvements.

Anxiety

At the start, according to the survey, guests’ anxiety levels were moderate. By the end, most had minimal or no anxiety symptoms. Overall, their anxiety scores on the surveys dropped by nearly half, showing a 49% average improvement.

Alcohol Anxiety

Depression

Depression scores also significantly decreased by 69%. Guests, on average, went from having “moderate to moderately severe” depression to having “minimal to mild” depression or not being depressed at all.

Alcohol Depression

Withdrawal

For many patients, alcohol withdrawal symptoms went from “mild” at the start to “minimal” or “none” by the end, with an average 77% reduction in alcohol withdrawal symptoms.

Alcohol Withdrawal

Simply put, our guests went home feeling less anxious and depressed than when they arrived. And they had far fewer alcohol withdrawal symptoms.

The Big Takeaway

The findings support our hunch that ibogaine could effectively reduce both the mental health symptoms and withdrawal symptoms of alcohol dependency. Being calmer and happier could improve patients’ commitment to treatment and reduce the likelihood of relapse. The study suggests ibogaine could be an effective part of a larger approach to recovery from alcoholism.

Why Ibogaine May Work

Ibogaine appears to create a “neuroplastic” effect in the brain. Ibogaine opens a “critical period” where the brain is more adaptable to forming new habits and changing old ones. This could help patients reshape their relationship with alcohol, making it easier to resist cravings or relapses.

Compared to other psychedelics like psilocybin (which opens these critical periods for about two weeks), ibogaine’s effects seem to last for up to four weeks, and clients continue receiving benefits from ibogaine treatment for up to three months, offering a longer time period for recovery and healing.

This study also aligns with research on psychedelics like MDMA and psilocybin. When combined with therapy, these drugs have been shown to help people with substance use disorders. Each psychedelic works a bit differently, but all seem to help address trauma, regulate emotions, and reduce addiction-related stress.

Ibogaine specifically appears to help people reflect on their lives and choices.

With this deeper understanding, people can understand the root causes of their addiction, and make changes.

Limitations of the Study

Every research study will have some limitations, which are important to disclose. Self-reported data, like surveys, can introduce biases. Guests may alter their answers—unintentionally or intentionally—to suit the story they’d like to tell themselves, or the story they think their doctors, nurses and researchers would like to hear. As well, guests who voluntarily and willingly seek ibogaine treatment for alcohol dependency to get better may differ from those who do not seek such treatment.

Conclusion

Ibogaine seems to have potential as a treatment for alcohol dependency by helping manage cravings, withdrawal, anxiety, and depression. Our findings suggest ibogaine could be a valuable option for people seeking new approaches to recovery from alcohol misuse.

/by
,

Understanding Ibogaine’s Pharmacological Mechanisms of Action for Holistic Healing

Ibogaine, a naturally occurring psychoactive substance derived from the African iboga plant, has garnered significant attention for its potential in treating various forms of addiction, including opioids, nicotine, and beyond.

Despite its complex pharmacological landscape, preliminary evidence suggests ibogaine’s multifaceted mechanisms of action offer a unique approach to addiction treatment.

Understanding Ibogaine’s
Mechanisms of Action


Opioid receptor systems

Ibogaine binds mu, kappa, and delta opioid receptors. However, its precise mechanisms at these receptor sites are still being defined. Ibogaine is considered a weak mu opioid receptor antagonist which is associated with anti-craving effects and opioid detoxification. Ibogaine is suspected to be a kappa opioid receptor agonist which is associated with analgesic, anti-depressant, anti-addictive, and neuroprotective effects.

Serotonin system

The serotonin transporter (SERT) is the site of action of the most common class of antidepressants known as SSRIs (selective serotonin reuptake inhibitors), which include Lexapro, Zoloft, and Prozac. Like SSRIs, ibogaine and its metabolite noribogaine are very strong serotonin reuptake inhibitors (i.e., they raise the level of serotonin). Ibogaine is a non-competitive inhibitor of SERT, which is suspected to contribute to ibogaine’s anti-depressant effects and improving negative mood states in post-acute withdrawal.

Dopamine system

Ibogaine demonstrates a binding affinity for the dopamine transporter (DAT), and has demonstrated biphasic effects on dopamine levels. Ibogaine is demonstrated to interact with DAT and result in adaptive dopamine signaling and restore functional activity in regions associated with opioid addiction and reward processing, such as the ventral tegmental area and nucleus accumbens.

NMDA antagonism

NMDA antagonism is associated with mitigation of withdrawal, opioid-reward, and drug-seeking behaviors. NDMA is also implicated in depression. Ketamine, which has a similar action, is utilized to mitigate opioid withdrawal symptoms, as well as to treat major depressive disorder.

GNDF stimulation

Ibogaine stimulates the production of glial-derived neurotrophic factor (GDNF). GDNF is identified as a treatment target for addiction. GDNF can restore damaged dopamine neurons. Many conditions can dysregulate or damage dopamine neurons, including chronic pain, Parkinson’s disease, severe drug addiction, and traumatic brain injury (TBI).

Nicotinic receptors

Ibogaine modulates nicotinic acetylcholine receptors, specifically as a noncompetitive antagonist for the α3β4 subtype. Antagonism of this receptor is implicated in mitigating and attenuating opioid withdrawal symptoms. Alternate treatments such as bupropion and mecamylamine are α3β4 antagonists often used in treatment of nicotine addiction.

Anti-inflammatory and antinociceptive effects

Opioid use disorder is associated with inflammation and pain states. Ibogaine demonstrates receptor affinity to sigma receptors, which are associated with modulating inflammatory responses. The NMDA antagonism of ibogaine may also possess anti-inflammatory and anti-nociceptive effects, addressing contributing or precipitating factors to opioid use and underlying factors maintaining dependency.

Psychedelic effects

The psychedelic effects of ibogaine are shown to induce insight into the underlying psychological contributors to addictive behavior. The psychedelic effects of ibogaine are likely mediated through a complex interaction among kappa opioid agonism, NMDA antagonism, and serotonergic transmission.

Conclusion

Ibogaine treatment presents a multifaceted approach to addiction recovery, targeting the complex interplay of neurochemical systems involved in dependency.

By addressing both the physiological and psychological dimensions of addiction, ibogaine offers a promising alternative for those seeking a path to recovery.

As research continues to unravel the intricacies of ibogaine’s mechanisms, its potential to transform addiction therapy becomes increasingly apparent.

For individuals grappling with addiction and seeking a holistic treatment option, exploring ibogaine’s healing potentials could be the first step toward a renewed life. At Beond, we’re committed to providing compassionate, evidence-based care, guiding our clients through their recovery journeys with ibogaine-assisted therapy.

Discover more about our programs and how ibogaine could be the key to unlocking your path to recovery.

Ready to explore a new horizon in addiction treatment? Contact us today to learn more about ibogaine treatment and how it can support your journey to long lasting recovery and healing.

/by
,

Exploring Ibogaine’s Brain Reset with Dr. Nolan Williams on The Tim Ferriss Show

Ibogaine works like a powerful reset button for your brain. 🧠 It acts on different parts of your brain that are involved in addiction, emotions, and memories. This unique interaction helps to rapidly and effectively address issues at their root, offering significant emotional and cognitive processing. It’s like getting a high-level overview of your life, helping you understand and confront deep-seated issues.

This introspective journey can lead to profound personal growth and healing, offering a new perspective on past experiences and traumas.

Watch the full interview with Dr. Nolan Williams: www.youtube.com/watch?v=UO7IgQ_x-Qg

“In addition to treating TBI, I think this may emerge as a broader neuro-rehab drug. I think it targets a whole host of different brain areas and can help us better understand how to treat other forms of PTSD, anxiety and depression that aren’t necessarily linked to TBI.” – Williams said.

Nolan Williams, MD is an associate professor within the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine and director of the Stanford Brain Stimulation Lab.

He has a broad background in clinical neuroscience and is triple board certified in general neurology, general psychiatry, and behavioral neurology and neuropsychiatry. Themes of his work include examining spaced learning theory and neurostimulation techniques, development and mechanistic understanding of rapid-acting antidepressants, and identifying objective biomarkers that predict neuromodulation responses in treatment-resistant neuropsychiatric conditions.

Nolan specializes in looking at cutting-edge treatments and new technologies that can be applied to treatment-resistant psychiatric disorders—so, treatment-resistant depression, disorders that are notoriously difficult to address, such as OCD, and many others.

/by

It’s time to heal.
Don’t wait. Speak with Beond.

BOOK A CALL WITH AN IBOGAINE EXPERT

PLEASE CONTACT THE PROFESSIONALS AT BEOND FOR MORE INFORMATION

Cancún, Quintana Roo, 77560, México

+1 (310) 707-1453
hello@beond.us